CellCentric’s p300/CBP bromodomain inhibitor is clearly differentiated from BET inhibitors.December 4th 2017:CellCentric today presents its latest pre-clinical efficacy data on drug Candidate CCS1477, at the AACR’s Annual Prostate Cancer meeting, Orlando. This novel inhibitor which targets the bromodomain of p300/CBP, is advancing to the clinic early 2018. Latest results continue to support CCS1477’s anti-cancer efficacy, as well as its clear differentiation versus other epigenetic-related inhibitors targeting bromodomains (BET inhibitors), such as JQ-1, iBET-151 and OTX-015.
CellCentric presents at the Prostate Cancer Foundation annual retreat, Washington DC .October 5th 2017:CellCentric presents new data on drug Candidate CCS1477 and its relevance to the aggressive, castrate-resistant form of prostate cancer, at the 24th Annual Prostate Cancer Foundation Scientific Retreat. The PCF meeting is the foremost scientific conference on the biology and treatment of prostate cancer. This is a closed, invitation only event which brings together the best researchers, physicians and medical oncologists from academia, non-profit organisations and industry.